The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against ChemoCentryx, Inc. (CCXI)
Retrieved on:
Wednesday, June 30, 2021
If you are a shareholder who suffered a loss, click here to participate.
Key Points:
- If you are a shareholder who suffered a loss, click here to participate.
- Its lead drug candidate is avacopan, which is developed as a potential treatment for ANCA-associated vasculitis (AAV).
- To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
- This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.